Skin expression data from psoriasis patients treated with IL-17A inhibitor
Psoriasis is a chronic, recurrent, inflammatory systemic disease that affects approximately 2-3% of the population worldwide. IL-17A plays a key pathogenic role in psoriasis, and IL-17A antigen have emerged as first-line agents for the treatment of moderate-to-severe plaque psoriasis.However, the associated mechanism underlying treatment-associated adverse and psoriasis relapse has not been reported.